corporate profile

Novocure (NASDAQ: NVCR) is a global oncology company striving to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields (TTFields). Our commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma (GBM) and for the treatment of adult patients with malignant pleural mesothelioma (MPM). In the U.S., our GBM therapy is approved by the U.S. Food and Drug Administration (FDA) under the Premarket Approval (PMA) pathway, and our MPM therapy is approved by the FDA under the Humanitarian Device Exemption (HDE) pathway. We continue to explore the safety and efficacy of TTFields for the treatment of multiple solid tumor cancers of the brain, thorax and abdomen.

corporate presentation
3
FDA-approved indications
22,000+
patients treated through December 2021
$535M
annual net revenues (2021)
$201M
annual R&D investments (2021)
4
phase 3 trials in new indications
view all

latest filings

date filing type filing download
May 12, 2022 4 Statement of Changes in Beneficial Ownership
May 09, 2022 4 Statement of Changes in Beneficial Ownership
April 28, 2022 8-K Current report filing
April 28, 2022 10-Q Quarterly Report
April 25, 2022 DEFA14A Additional Proxy Soliciting Materials (definitive)
April 25, 2022 DEF 14A Proxy Statement (definitive)
April 14, 2022 3 Initial Statement of Beneficial Ownership
April 14, 2022 PRE 14A Proxy Statement – Notice of Shareholders Meeting (preliminary)
April 13, 2022 8-K Current report filing
April 11, 2022 SC 13G/A Amended Statement of Ownership
April 07, 2022 8-K Current report filing
March 23, 2022 8-K Current report filing
March 11, 2022 4 Statement of Changes in Beneficial Ownership
March 11, 2022 4 Statement of Changes in Beneficial Ownership
March 09, 2022 4 Statement of Changes in Beneficial Ownership
mission, vision and values

mission

Together with our patients, we strive to extend survival in some of the most aggressive forms of cancer by developing and commercializing our innovative therapy.

vision

Patient-forward: aspiring to make a difference in cancer

learn more

contact us

investorinfo@novocure.com
610-723-7427

sign up for email alerts

To receive notifications via email, enter your email address and select at least one subscription below. After submitting your information, you will receive an email. You must click the link in the email to activate your subscription. You can sign up for additional subscriptions at any time.